ConceptioArchiveClinicalTrials.gov
ClinicalTrials.govpublic full text

Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment

National Cancer Institute (NCI) · 2023
ClinicalTrials.gov · Datasets · License: Public Domain · 2023
Open Source ↗
recurrent b-cell non-hodgkin lymphoma, recurrent diffuse large b-cell lymphoma germinal center b-cell type, recurrent follicular lymphoma, recurrent non-hodgkin lymphoma, recurrent primary cutaneous t-cell non-hodgkin lymphoma, recurrent t-cell non-hodgkin lymphoma, recurrent transformed non-hodgkin lymphoma, refractory b-cell non-hodgkin lymphoma, refractory diffuse large b-cell lymphoma germinal center b-cell type, refractory follicular lymphoma, refractory non-hodgkin lymphoma, refractory primary cutaneous t-cell non-hodgkin lymphoma
This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗
Record · ID 837057
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.